ATEA PHARMACEUTICALS INC's ticker is AVIR and the CUSIP is 04683R106. A total of 70 filers reported holding ATEA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 3.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $99,858 | -57.5% | 33,286 | -47.0% | 0.00% | – |
| Q2 2023 | $235,014 | +13.4% | 62,838 | +1.6% | 0.00% | – |
| Q1 2023 | $207,288 | -21.3% | 61,877 | +12.9% | 0.00% | – |
| Q4 2022 | $263,511 | +52.1% | 54,784 | +79.9% | 0.00% | – |
| Q3 2022 | $173,300 | -14.2% | 30,457 | +7.3% | 0.00% | -100.0% |
| Q2 2022 | $202,000 | +12.8% | 28,385 | +14.7% | 0.00% | – |
| Q1 2022 | $179,000 | -19.0% | 24,749 | 0.0% | 0.00% | – |
| Q4 2021 | $221,000 | -75.3% | 24,749 | -2.8% | 0.00% | -100.0% |
| Q3 2021 | $893,000 | +63.3% | 25,474 | 0.0% | 0.00% | +100.0% |
| Q2 2021 | $547,000 | +39.5% | 25,474 | +300.9% | 0.00% | 0.0% |
| Q1 2021 | $392,000 | +94.1% | 6,354 | +31.6% | 0.00% | – |
| Q4 2020 | $202,000 | – | 4,828 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 2,485,638 | $17,648,000 | 2.07% |
| EcoR1 Capital, LLC | 6,340,639 | $45,019,000 | 1.55% |
| CM Management, LLC | 200,000 | $1,420,000 | 1.51% |
| K2 PRINCIPAL FUND, L.P. | 1,606,059 | $11,403,000 | 1.26% |
| Cormorant Asset Management, LP | 1,547,181 | $10,985,000 | 0.83% |
| Privium Fund Management (UK) Ltd | 61,284 | $435,000 | 0.49% |
| Atom Investors LP | 30,911 | $219,000 | 0.10% |
| FEDERATED HERMES, INC. | 3,588,131 | $25,476,000 | 0.07% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 347,612 | $2,468,000 | 0.06% |
| BALYASNY ASSET MANAGEMENT L.P. | 1,799,507 | $12,777,000 | 0.04% |